Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations?

Editorial

Bruce E Johnson et al. J Clin Oncol. 2005.

. 2005 Oct 1;23(28):6813-6.

doi: 10.1200/JCO.2005.97.008. Epub 2005 Sep 6.

No abstract available

Comment in

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
Shepherd FA, Tsao MS. Shepherd FA, et al. J Clin Oncol. 2006 Mar 1;24(7):1219-20; author reply 1220-1. doi: 10.1200/JCO.2005.04.4420. J Clin Oncol. 2006. PMID: 16505443 No abstract available.

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, Bunn PA Jr, Franklin WA, Crowley J, Gandara DR; Southwest Oncology Group. Hirsch FR, et al. J Clin Oncol. 2005 Oct 1;23(28):6838-45. doi: 10.1200/JCO.2005.01.2823. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998906 Clinical Trial.
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Takano T, et al. J Clin Oncol. 2005 Oct 1;23(28):6829-37. doi: 10.1200/JCO.2005.01.0793. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998907